The "Fast Money" traders give their final trades of the day.» Read More
The stock market deteriorated in the final 20 minutes of trading with the Dow closing with triple digit losses.
Stocks sold off in the final hour of trading, an hour that has become known for wild, unpredictable swings, as a new government plan to juice money-market funds and some dismal corporate outlooks kept investors on edge.
Stocks retreated after a fleeting uptick as investors digested a slew of earnings and some dismal outlooks and signs of a thawing in the credit markets.
Stocks turned lower again after paring most of their losses amid more signs of thawing in the seized up credit markets.
U.S. companies ranging from chemicals like Du Pont, to pharmas like Pfizer and Schering Plough, and financials like Fifth Third and BlackRock, reported earnings Tuesday.
U.S. stock market index futures pointed to a lower open for Wall Street Tuesday as worries over the health of the economy offset enthusiasm after news of a possible second stimulus package.
Investors Tuesday will again be watching for progress in the credit markets, where the trickle from a slow thaw has been enough to end the drought of buyers in the stock market.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
The Dow made another triple digit move on Monday this time soaring more than 400 points higher.
Stocks rallied to the finish line after another volatile session as signs began to emerge that credit markets may be defrosting. The Dow gained more than 400 points.
Stocks were higher in a wobbly session as investors digested remarks from Federal Reserve Chairman Ben Bernanke and Treasury Secretary Hank Paulson.
Despite a slowing economy, drug stocks such as Abbott Labs and Genentech posted positive earnings reports. Is health care the best defensive play in this market?
Following are the “Fast & Furious” trades - hot ways to play next week's market moving events.
A drug stock with a safe dividend? That's just what you need in this tough environment.
Some stocks are more popular than others. But that doesn't mean they're always the best shares to hold. Michael Farr, president of Farr, Miller and Washington, gave his assessment of five of the most widely held companies.
I don't think Eli Lilly will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration.
Since there should really be no compelling reason to blog or report on Dendreon and Provenge for quite awhile, here's one last hurrah.
Which stocks have been unfairly punished over the last three trading days?
Wall Street struggled with another day of selling as panic seemed to accelerate into the final minutes of trading.
Pretty much all of biopharma is caught in the downdraft of the markets today with the notable exception of Dendreon (data) and ImClone Systems (a deal).